JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation.
Keigo IkedaKunihiro HayakawaMaki FujishiroMikiko KawasakiTakuya HiraiHiroshi TsushimaTomoko MiyashitaSatoshi SuzukiShinji MorimotoNaoto TamuraKenji TakamoriHideoki OgawaIwao SekigawaPublished in: BMC immunology (2017)
Modulation of type I IFN signalling via JAK-STAT inhibition may exert a beneficial effect in SLE patients, and our results suggest that TOFA could be utilised for the development of new SLE-specific therapeutic strategies.
Keyphrases
- systemic lupus erythematosus
- disease activity
- end stage renal disease
- ejection fraction
- dendritic cells
- immune response
- newly diagnosed
- chronic kidney disease
- prognostic factors
- cell proliferation
- signaling pathway
- genome wide
- patient reported outcomes
- copy number
- dna methylation
- metabolic syndrome
- skeletal muscle
- adipose tissue